Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01314586 · ClinicalTrials.gov registry record · NA
Flax Lignans and Heart Health
A NA study, sponsored by Iowa State University.
- Completed
- Registry status
- NA
- Development phase
- 93
- Enrollment target
NCT01314586 is a NA study that has completed, run by Iowa State University. The registered enrollment target is 93 participants.
The verdict
NCT01314586, a NA study, has completed, sponsored by Iowa State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 93 participants
- Enrollment target
Study Summary
Purpose: To demonstrate the efficacy of Beneflax™ flaxseed lignan (SDG) concentrate to lower serum cholesterol levels. Background: Flaxseed has been studied for various health benefits in humans, including prostate health, glucose control, and cardiovascular health. Cholesterol levels and high blood pressure are known to be risk factors for cardiovascular disease. Whole flaxseed has had variable effects on serum lipid levels, perhaps a consequence of variations in the amounts of secoisolariciresinol diglucoside (SDG) found in different flax cultivars, making the study of this bioactive compound difficult. Hypothesis: Flaxseed lignan (SDG) extract (Beneflax) significantly lowers total and LDL cholesterol. Flaxseed lignans also lower blood pressure and fasting glucose levels.
Interventions
- DIETARY_SUPPLEMENT secoisolariciresinol diglucoside-containing extract of flaxseed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2007-12 |
| Est. Completion | 2009-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01314586
The ClinicalTrials.gov registry entry for NCT01314586 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Iowa State University, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which secoisolariciresinol diglucoside-containing extract of flaxseed is the first listed.
NCT01314586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01314586 about?
NCT01314586 is a clinical study titled "Flax Lignans and Heart Health". Purpose: To demonstrate the efficacy of Beneflax™ flaxseed lignan (SDG) concentrate to lower serum cholesterol levels. Background: Flaxseed has been studied for various health benefits in humans, including prostate health, glucose control, and cardiovascular health. Cholesterol levels and high bloo...
What is the current status of trial NCT01314586?
This trial is currently completed. It is a NA study. The enrollment target is 93 participants. The study started on 2007-12. Estimated completion is 2009-11.
What interventions are being tested in trial NCT01314586?
The interventions under investigation include: secoisolariciresinol diglucoside-containing extract of flaxseed (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01314586?
This trial is sponsored by Iowa State University, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.